Budesonide – Formoterol


Title Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Comments Erratum in: Eur Respir J. 2003 May;21(5):912.
Authors Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H
Source The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology
Date of publication 2003 Jan
Volume 21
Issue 1
Pages 74-81
Abstract The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In a 12-month, randomised, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 yrs, mean forced expiratory volume in one second (FEV1) 36% predicted normal), patients received two inhalations twice daily of either budesonide/formoterol (Symbicort) 160/4.5 microg (delivered dose), budesonide 200 microg (metered dose), formoterol 4.5 microg or placebo. Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta2-agonist and safety variables were recorded. Budesonide/formoterol reduced the mean number of severe exacerbations per patient per year by 24% versus placebo and 23% versus formoterol. FEV1 increased by 15% versus placebo and 9% versus budesonide. Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol. Improvements in morning and evening PEF versus comparators were maintained over 12 months. Budesonide/formoterol decreased all symptom scores and use of reliever beta2-agonists significantly versus placebo and budesonide, and improved HRQL versus placebo. All treatments were well tolerated. These results suggest a role for budesonide/formoterol in the long-term management of moderate-to-severe chronic obstructive pulmonary disease.
Medical Subject Headings (MeSH) Administration, Inhalation; Adrenal Cortex Hormones[administration & dosage][*therapeutic use]; Adrenergic beta-Agonists[administration & dosage][therapeutic use]; Budesonide[administration & dosage][*therapeutic use]; Double-Blind Method; Drug Combinations; Ethanolamines[administration & dosage][*therapeutic use]; Forced Expiratory Volume; Peak Expiratory Flow Rate; Pulmonary Disease, Chronic Obstructive[*drug therapy]; Time Factors
Mesh check words: Female; Humans; Male; Middle Aged
Correspondence address Dept Lung Diseases, Voivodeship Specialist Hospital, Radom, Poland.
Accession number PUBMED  12570112
Publication type Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov’t
Cochrane code SR-AIRWAYS
ID CN-00435216
CLIB_SPECIFIC___________ EFFICACY AND SAFETY OF BUDESONIDEFORMOTEROL IN THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

One thought on “Budesonide – Formoterol”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s